The mission of NuSomnea is to revolutionize the diagnosis and management of Obstructive Sleep Apnea (OSA) by replacing overnight sleep tests with a simpler, easier, less costly and more accurate test.
The NuSomnea test involves the assay of multiple urinary peptide biomarkers, providing comparable or greater accuracy for OSA diagnosis than the standard polysomnography (PSG) procedure. A prospective, controlled, proof-of-concept study conducted in 120 pediatric subjects has demonstrated 100% sensitivity and 96.5% specificity for diagnosing OSA.
Because the cost is significantly lower and the ease of administration is significantly more convenient than that of a PSG, this new test can be utilized globally as both a diagnostic tool and a disease management tool, to monitor therapy effectiveness and improve patient outcomes.
The company has secured the exclusive intellectual property rights for the assay. Because one of the co-founders is already a CLIA-certified lab, NuSomnea will be able to rapidly refine, validate and introduce this test. Using the reference lab as an initial business model will also provide greater flexibility for commercialization and distribution of the tests.
The urine biomarker test will initially focus on the pediatric OSA population, the prevalence of which is growing in the USA and for which the diagnostic options remain costly and inefficient. Development of a test for adults is a top clinical priority.
Company’s Keywords:
healthcare, personal health, medical devices, diagnostics, medical, health care, medical device, clia, obstructive sleep apnea
0
medical devices
2012
Your request has been submitted successfully.
Own or work here?